Abstract: An isolated and purified human receptor tyrosine kinase is described. A cDNA sequence which encodes the native polypeptide is disclosed as well as the structural coding region and the amino acid residue sequence of the tyrosine kinase. Methods are provided which employ novel sequences to identify compounds that modulate the biological and/or pharmacological activity of the tyrosine kinase and hence regulate cellular and tissue physiology. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the kinase, are described which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the biological molecule.

Abstract: An isolated and purified human receptor tyrosine kinase is described. A cDNA sequence which encodes the native polypeptide is disclosed as well as the structural coding region and the amino acid residue sequence of the tyrosine kinase. Methods are provided which employ novel sequences to identify compounds that modulate the biological and/or pharmacological activity of the tyrosine kinase and hence regulate cellular and tissue physiology. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the kinase, are described which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the biological molecule.

Abstract: An isolated and purified human receptor tyrosine kinase is described. A cDNA sequence which encodes the native polypeptide is disclosed as well as the structural coding region and the amino acid residue sequence of the tyrosine kinase. Methods are provided which employ novel sequences to identify compounds that modulate the biological and/or pharmacological activity of the tyrosine kinase and hence regulate cellular and tissue physiology. Biologically-effective antisense molecules, as well as dominant negative mutant versions of the kinase, are described which are suitable for therapeutic use. The invention is also related to the diagnosis, study, prevention, and treatment of pathophysiological disorders related to or mediated by the biological molecule.

Abstract: Human E3 ubiquitin protein ligase is described. A structural region which encodes the polypeptide is disclosed as well as the the amino acid residue sequence of the protein ligase. Methods are provided which employ the sequences to identify compounds that modulate a biological and/or pharmacological activity of the molecule and hence regulate cellular and tissue physiology. The invention is also drawn toward the diagnosis, prevention, and treatment of pathophysiological disorders mediated by E3 ubiquitin protein ligases.

Abstract: A novel human E3 ubiquitin protein ligase is provided as well as a nucleic acid structural region which encodes the polypeptide and the amino acid residue sequence of the human biomolecule. Methods are provided to identify compounds that modulate the biological activity of the molecule and hence regulate cellular and tissue physiology.